MERRIMACK PHARMACEUTICALS IN's ticker is and the CUSIP is 590328AA8. A total of 10 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $22,928,000 | +19.5% | 25,762,000 | 0.0% | 0.34% | +19.9% |
| Q2 2017 | $19,188,000 | -9.6% | 25,762,000 | 0.0% | 0.29% | -7.1% |
| Q1 2017 | $21,221,000 | -4.5% | 25,762,000 | +10.7% | 0.31% | -22.0% |
| Q4 2016 | $22,216,000 | +417.7% | 23,262,000 | +564.6% | 0.40% | +480.9% |
| Q3 2016 | $4,291,000 | -40.6% | 3,500,000 | -50.0% | 0.07% | -20.9% |
| Q4 2013 | $7,228,000 | – | 7,000,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 25,762,000 | $22,928,000 | 0.34% |
| WOLVERINE ASSET MANAGEMENT LLC | 9,998,000 | $8,555,000 | 0.10% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,331,000 | $1,138,000 | 0.04% |
| PUTNAM INVESTMENTS LLC | 2,876,000 | $2,459,000 | 0.01% |
| LAZARD ASSET MANAGEMENT LLC | 3,300,000 | $2,838,000 | 0.01% |
| AMERIPRISE FINANCIAL INC | 3,320,000 | $2,839,000 | 0.00% |
| UBS Group AG | 1,000 | $1,000 | 0.00% |
| Jefferies Group LLC | 10,000 | $8,000 | 0.00% |
| JPMORGAN CHASE & CO | 2,015,000 | $1,730,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 7,000 | $7,000 | 0.00% |